Table 1 Patient demographics

From: Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

Parameter

TMZ+IFN

TMZ+PEG

Number of patients

34

29

Age: median (range)

55 (17–69)

56 (20–67)

Gender: M/F (%)

25 : 9 (74:26)

16 : 13 (55 : 45)

KPS

  

 Median

80

90

 100%

3 (9%)

5 (17%)

 90%

7 (21%)

16 (55%)

 80%

17 (50%)

5 (17%)

 70%

7 (21%)

3 (10%)

Maximum prior resection

 Biopsy

2 (6%)

5 (17%)

 Subtotal resection

20 (59%)

9 (31%)

 Gross total resection

12 (35%)

15 (52%)

Number of prior chemotherapies

 0

9 (26%)

14 (48%)

 1

24 (71%)a

14 (48%)b

 2

1 (3%)

1 (3%)

  1. aPrior chemotherapies included: topotecan, BCNU, cisplatinum, procarbazine+CCNU+vincristine (PCV), hydroxyurea, marimastat, 6-thioguanine, 13-cis-retinoic acid, carboplatin, and etoposide.
  2. bPrior chemotherapies included: celecoxib, gefitinib, BCNU, CCNU, vincristine, 13-cis-retinoic acid, PCV, tipifarnib, and erlotinib.